NCEL NewcelX Ltd. Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1783036 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY—
TTM net income YoY-15.3%
TTM EPS YoY-11.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-134.4%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets36.7%
Debt / equity0.00x
Current ratio0.76x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.33x
Accruals ratio-89.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $1.13M | $992,000 |
| SG&A expense | $1.35M | $805,000 |
| Operating income | -$2.56M | -$2.07M |
| Interest expense | — | $45,054 |
| Pretax income | — | -$7.20M |
| Net income | -$8.30M | -$7.20M |
| EBITDA | -$2.51M | -$1.65M |
| EPS (basic) | 2.16 | 2.43 |
| EPS (diluted) | 2.16 | 2.43 |
| Weighted avg. shares (diluted) | 3.84M | 2.96M |
| Balance sheet | ||
| Cash & equivalents | $2.20M | $650,000 |
| Current assets | $3.18M | $780,000 |
| PP&E, net | $95,000 | $123,000 |
| Goodwill | $1.73M | — |
| Total assets | $11.45M | $903,000 |
| Current liabilities | $4.20M | $8.90M |
| Short-term debt | $355,000 | $7.73M |
| Total liabilities | $4.20M | $8.90M |
| Shareholders' equity | $7.25M | -$8.00M |
| Shares outstanding | 4.80M | 2.96M |
| Cash flow statement | ||
| Operating cash flow | -$2.77M | -$1.07M |
| Capital expenditure | $8,000 | $6,000 |
| Free cash flow | -$2.77M | -$1.07M |
| Investing cash flow | $1.70M | -$6,000 |
| Financing cash flow | $2.63M | $450,000 |
| Depreciation & amortization | $55,000 | $413,000 |
| Stock-based compensation | $765,000 | $208,000 |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.